October 31, 2022
Mosaic ImmunoEngineering’s Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company’s Novel Immuno-Oncology Platform
May 5, 2022
Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University
February 2, 2022
Newly Published Data Further Support Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma
November 1, 2021
Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation
October 20, 2021
Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference
October 12, 2021
Spotlight Presentation at the World Molecular Imaging Congress Highlights Mosaic ImmunoEngineering’s Immuno-Oncology and Modular Vaccine Platform Candidates
October 6, 2021
Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego
October 1, 2021
Upcoming Presentation at the World Molecular Imaging Congress to Highlight Mosaic ImmunoEngineering’s Lead Immuno-Oncology and Modular Vaccine Platform COVID-19 Vaccine Candidates
September 27, 2021
Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology
September 23, 2021
Mosaic ImmunoEngineering Announces Publication of Data Supporting the Potential of its SARS-CoV-2 Vaccine Candidates under its Modular Vaccine Platform
September 21, 2021
Mosaic ImmunoEngineering Expands Its Modular Vaccine Platform (MVP) Through New Technology Licensing Agreement with the University of California San Diego
June 29, 2021
Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering’s Lead Intratumoral Immunotherapy Candidate, MIE-101
June 28, 2021
Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting
June 15, 2021
Mosaic ImmunoEngineering Inc. Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D. to Its Board of Directors
January 19, 2021
Mosaic ImmunoEngineering Inc. Announces Upgrade to OTCQB Venture Market and Upcoming Presentation at the B. Riley Oncology Investor Conference
December 30, 2020
Mosaic ImmunoEngineering Inc. Announces Stock Symbol Change to “CPMV”
December 14, 2020
Mosaic ImmunoEngineering Inc. Provides an Overview of Development Plans for Advancing Its Lead Immuno-Oncology Product Candidate MI-O-101
December 1, 2020
Patriot Scientific Corporation Announces Name Change to "Mosaic ImmunoEngineering Inc.", Stock Symbol Change and Reverse Stock Split
August 31, 2020
Mosaic ImmunoEngineering Inc. signs license-option to advance novel immunotherapy to treat cancer and infectious diseases
August 24, 2020
Patriot Scientific Corporation and Mosaic ImmunoEngineering Inc. Enter into Definitive Merger Agreement
